Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 552 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE REGISTRATION FILING SUBMITTED IN HONG KONG
Regulatory Filings
2026-06-02 English
Point d'étape stratégique pour Biophytis : Dossier de joint-venture déposé à Hong Kong
Regulatory Filings
2026-06-02 French
Information on the Annual Financial Statements 2025
Report Publication Announcement Classification · 94% confidence The document is a press release informing the market of a delay in publishing the 2025 annual financial statements and postponement of the AGM. It contains no actual financial data or statements but rather an announcement about the timing of the report’s publication. This matches the definition of a Report Publication Announcement (RPA).
2026-05-29 English
Information sur les comptes annuels 2025
Report Publication Announcement Classification · 90% confidence The document is a press release announcing a delay in finalizing and publishing the company’s annual accounts for 2025 and stating when the report will be issued. It contains no actual financial statements or detailed report content, but rather informs investors and regulators of the revised timing for publication. This aligns with a Report Publication Announcement (RPA) rather than the actual annual report or other filing type.
2026-05-29 French
BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE
Capital/Financing Update Classification · 90% confidence The document is a press release detailing amendments to the terms of a €2 million bond financing facility (revolving credit structure, interest rate reduction, past amendments, usage, capacity). It is a direct update on the company’s fundraising and capital structure management, rather than a full annual or interim report, regulatory attestation, or proxy material. Therefore it best fits the Capital/Financing Update category.
2026-05-27 English
BIOPHYTIS MODIFIE SA LIGNE DE FINANCEMENT AVEC HEXAGON CAPITAL FUND POUR RENDRE RENOUVELABLE SA CAPACITE DE TIRAGE DE 2M€
Capital/Financing Update Classification · 85% confidence The document is a corporate press release announcing modifications to an existing debt financing facility (line of simple bonds) with Hexagon Capital Fund, including making the line renewable and reducing the interest rate. It contains detailed amendments and background on the financing contract rather than financial statements, call transcripts, or AGM materials. This clearly falls under a Capital/Financing Update.
2026-05-27 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.